Tower Research Capital LLC TRC Acquires 7,368 Shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP)

Tower Research Capital LLC TRC raised its holdings in PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) by 344.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,508 shares of the company’s stock after buying an additional 7,368 shares during the quarter. Tower Research Capital LLC TRC’s holdings in PMV Pharmaceuticals were worth $29,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the business. Connor Clark & Lunn Investment Management Ltd. increased its position in PMV Pharmaceuticals by 3.5% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 169,699 shares of the company’s stock valued at $1,042,000 after purchasing an additional 5,737 shares during the period. Independent Advisor Alliance purchased a new stake in PMV Pharmaceuticals in the fourth quarter worth about $39,000. SG Americas Securities LLC purchased a new stake in PMV Pharmaceuticals in the fourth quarter worth about $65,000. Algert Global LLC bought a new stake in PMV Pharmaceuticals during the 3rd quarter valued at approximately $171,000. Finally, PEAK6 Investments LLC purchased a new position in shares of PMV Pharmaceuticals during the 3rd quarter worth approximately $200,000. 90.20% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

PMVP has been the topic of several research reports. Jefferies Financial Group assumed coverage on PMV Pharmaceuticals in a research report on Friday, April 12th. They set a “buy” rating and a $5.00 price target on the stock. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of PMV Pharmaceuticals in a research report on Thursday, March 7th.

PMV Pharmaceuticals Trading Up 6.4 %

PMVP traded up $0.12 during midday trading on Friday, reaching $1.99. The company’s stock had a trading volume of 1,272,571 shares, compared to its average volume of 436,050. PMV Pharmaceuticals, Inc. has a 1 year low of $1.18 and a 1 year high of $9.72. The stock’s 50-day moving average is $1.72 and its 200-day moving average is $1.96. The firm has a market capitalization of $102.37 million, a price-to-earnings ratio of -1.37 and a beta of 1.56.

PMV Pharmaceuticals (NASDAQ:PMVP) last posted its quarterly earnings results on Thursday, February 29th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.08. As a group, equities research analysts forecast that PMV Pharmaceuticals, Inc. will post -1.44 earnings per share for the current fiscal year.

PMV Pharmaceuticals Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.